### Health Related Quality of Life Assessment in Egyptian Recipients after Living Donor Liver Transplantation

**Thesis** 

Submitted for partial fulfillment of Master Degree in **Tropical**Medicine

By

**Peter William Gaber Khalil** M.BB.Ch.

### **Under Supervision of**

### Prof. Eman Mohamed El-Said El-Gindy

Professor of Tropical Medicine Faculty of Medicine Ain Shams University

### **Dr.Iman Mohammad Fawzy Montasser**

Lecturer of Tropical Medicine Faculty of Medicine Ain Shams University

### Dr. Reem El-Sayed Mohamed Hashem

Lecturer of Psychiatry Faculty of Medicine Ain Shams University

Faculty of Medicine Ain Shams University 2015



## Acknowledgement

First, thanks are all due to Allah for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

I would like to express my deep appreciation to **Prof. Dr. Eman Mohamed El-Said El-Gindy,** Professor of Tropical Medicine, Ain Shams University for her detailed and constructive comments, professional guidance and for her valuable support throughout this work.

I am deeply grateful to, **Dr. Iman Mohamed Fawzy Montasser**, Lecturer of Tropical Medicine, Ain Shams University. I am indebted to her constructive criticism and continuous unlimited help and for giving me the privilege to work under her supervision. I appreciate her active participation in providing me with a lot of knowledge.

I would like to express my deep appreciation to, **Dr. Reem El-Sayed Mohamed Hashem**, Lecturer of Psychiatry, Ain Shams University, for her faith in my ability, her scientific help, meticulous supervision and constructive criticism which helped me to accomplish this work.

I would like to express my deepest thanks to all patients and all the staff members in Ain Shams Center of Organ Transplantation in Ain Shams Specialized Hospital for their help and cooperation to accomplish this work. Last but not least, I would like to express my gratitude and appreciation to all those who helped me directly or indirectly in accomplishing this work.



### **Contents**

List of Abbreviations	i
List of Tables	iii
List of Figures	vi
List of Algorithms	vii
Introduction & Aim of the Study	1
Review of Literature	5
Chapter (I)	
* End Stage Liver Disease	5
Chapter (II)	
* Liver Transplantation	26
Chapter (III)	
* Health Related Quality of Life	54
Patients & Methods	67
Results	83
Discussion	108
Summary	121
Conclusion	125
Recommendations	126
References	127
Arabic Summary	

### **List of Abbreviations**

AIH : Autoimmune Hepatitis ALT : Alanine Transferase

AST : Aspartate Transferase

BDI : Beck Depression Inventory

CMV : Cytomegalovirus

CNI : Calcineurin Inhibitor

CTP : Child-Turcotte-Pugh

DM : Diabetes Mellitus

ESLD : End Stage Liver Disease

HBIg : Hepatitis B Immune globulin

HBV : Hepatitis B Virus

HCC : Hepato Cellular Carcinoma

HCV : Hepatitis C Virus

HIV : Human Immunodeficiency Virus

HRQOL : Health-Related Quality of Life

INR : International Normalizing Ratio

LDLT : Living Donor Liver Transplantation

LT : Liver Transplantation

MELD : Model for End-Stage Liver Disease

OLT : Orthotopic Liver Transplantation

PBC : Primary Biliary Cirrhosis

PROMIS: Patient-Reported Outcomes Measurement

**Information System** 

## List of Abbreviations (Cont.)

PSC : Primary Sclerosing Cholangitis

PVT : Portal Vein Thrombosis.

QOL : Quality of Life

SF-36 : Short Form-36

SPSS : Statistical Package for Social Sciences

UNOS : United Network for Organ Sharing

WHO : World Health Organization

### List of tables

Table	Title	Page
1	Common complications of cirrhosis	6
2	Child-Pugh classification of severity of cirrhosis	25
3		20
	Indications for liver transplantation	29
4	Indications for liver transplantation according to disease severity	30
5	Pre-liver transplant evaluation	36
6	Histologic rejection activity index for liver transplants	40
7	Evaluation of fever after liver transplantation	45
8	Risk factors for the development of biliary complications after liver transplantation	47
9	Assessment Tools Available to Evaluate HRQOL in Orthotopic Liver Transplant Recipients	57
10	Socio-demographic characteristics of the studied patients	84
11	Medical characteristics of the studied patients	85
12	Initial hepatopathy of the studied patients at time of transplantation	85
13	SF-36 measures in the studied patients	87
14	Correlation between health-related	91
	quality of life and psychological	
	outcomes six months after liver	
	transplantation	
15	Relations between gender and HRQOL scores before liver transplantation	92

# List of tables (Cont.)

Table	Title	Page
16	Relations between gender and HRQOL	93
	scores six months post liver	
	transplantation	
17	Correlation coefficient between age and	94
	different aspects of the SF-36	
18	Relations between initial hepatopathy	95
	and HRQOL scores before liver	
10	transplantation	
19	Relations between initial hepatopathy	96
	and HRQOL scores six months post liver	
20	transplantation	07
20	Relations between working status and	97
	HRQOL scores before liver	
21	transplantation  Relations between working status and	98
21	Relations between working status and HRQOL scores six months post liver	90
	transplantation	
22	Relations between educational level and	99
	HRQOL scores before liver	
	transplantation	
23	Relations between educational level and	100
	HRQOL scores six months post liver	
	transplantation	
24	Relations between disease severity	101
	assessed by MELD score and HRQOL	
	scores before liver transplantation	
25	Relations between disease severity	102
	assessed by MELD score and HRQOL	
	scores six months post liver	
	transplantation	
26	Relations between Child score and	103
	HRQOL scores before liver	
	transplantation	

## List of tables (Cont.)

Table	Title	Page
27	Relations between Child score and HRQOL scores six months post liver transplantation	104
28	HRQOL scores one year after liver transplantation	105

## **List of Figures**

Fig.	Title	Page
1	Clinical features of hepatic	14
	encephalopathy	
2	Components evaluated by SF-36 to	59
	determine disease effects on health-	
	related quality of life	
3	SF-36 mental and physical component	62
	scores	
4	SF-36 measures in the study group	89
	before, one month and six months after	
	liver transplantation	
5	Beck Depression Inventory scores (BDI)	90
	of the studied group before, one month	
	and six months after liver transplantation	
6	SF-36 measures in the study group ( $n = 1$	106
	17) before, one month, six months and	
	one year after liver transplantation	
7	Beck Depression Inventory scores (BDI)	107
	of the studied group $(n = 17)$ before, one	
	month, six months and one year after	
	liver transplantation	

# **List of Algorithms**

Algorithm	Title	Page
1	Treatments for hepatic hydrothorax	11
2	Evaluation of suspected biliary	48
	obstruction after liver transplantation	

### Introduction

Liver transplantation has emerged over the past several decades as a viable treatment option for patients with acute liver failure and end stage liver disease. Initial progress and growth were limited by technical difficulties and an inherent learning curve in the management of patients in the post-transplantation period. Improvements in transplantation outcomes have yielded a greater treatment demand and a new challenge, organ shortage (*Dove and Brown*, 2012).

Although liver transplantation has proven to be a great success in a relatively short period of development, it should not be considered as either the initial or primary treatment modality for most liver diseases. Other than in a few specific disorders (e.g amyloidosis, hyperoxaluria, urea cycle defects and disorders of branched chain amino acids), transplantation is a therapy for disease complications rather than of the primary illness (*Dove and Brown*, 2012).

Thus, the selection of a transplant candidate is a risk-benefit analysis, in which the inherent risks of surgery, recurrent disease, and long-term immunosuppression must be weighed against the potential benefits of transplantation. These benefits differ for each patient but include improvements in survival, prevention of long-term complications, and better health-related quality of life (HRQOL) (*Dove and Brown*, 2012).

The most commonly used prognostic model for estimating disease severity and survival is the Model for End – stage Liver Disease (MELD). The MELD score uses a patients laboratory values for serum bilirubin, serum creatinine, and international normalized ratio for prothrombin time (INR) in a log transformed equation to estimate likelihood of three-month survival. Higher MELD scores have been associated with decrease survival rates. Implementation of MELD for organ

allocation has decreased pretransplant mortality without having a negative impact on post transplant mortality (*Kiran and Patrick*, 2012).

An understanding of the issues pertaining to quality of life is essential for any disease or health condition. It is particularly important in orthotopic liver transplantation (OLT) recipients. Health-related quality of life (HRQOL) is a quantitative conversion of a patient's self-assessment of his or her physical, functional, social, and psychological dimensions of life. It is a mean of studying how a patient perceives his or her health status and other nonmedical aspects of his or her life. As survival times plateau for many chronic diseases, HRQOL is now included in clinical trials as yet another form of medical outcome assessment. HRQOL research presents a challenging goal for clinicians as it is necessary to convert information based on patient self-assessment and subjective reports into a quantitative measurement that can standardized and applied to large patient populations. In addition, its interventions and outcomes are based on patient driven objectives, priorities, interpretations, and satisfaction rather than solely physician-based medical objectives and goals such as mortality, morbidity, length of life, and survival rates (Bownik and Saab, 2009).

There are number of tools used to study HRQOL in transplant recipients. These tools are stratified into 2 categories: generic and disease-specific instruments. The SF-36 survey is the most frequently used HRQOL instrument for OLT recipients. Disease-specific instruments sensitive in their assessment of the individual effects of a specific disease or disease state, certain impairing characteristics of a disease, or a patient's response to a specific intervention. One of the most recognized instruments used in patients with liver disease is the Chronic Liver Disease Questionnaire (CLDQ) (Schulz et al., 2008).

#### Introduction and Aim of the Work

Pretransplantation health-related quality of life scores are affected by the etiology of liver cirrhosis, with hepatocellular and cholestatic etiologies having higher HRQOL scores than alcohol or viral hepatitis etiologies. Posttransplantation health-related quality of life scores are not affected by the etiology of the original liver cirrhosis, but transplant recipient scores continue to remain significantly lower than those of healthy controls (*Bownik and Saab*, 2009).

During the first 6 months after liver transplantation, the majority of physical and mental components of health-related quality of life scores improve, but these increases are not sustained in the long term. Hepatitis C as an indication for liver transplantation is an independent factor in decreasing posttransplantation health-related quality of life scores (*Bownik and Saab*, 2009).

Established evidence shows that a high level of post liver transplantation anxiety is harmful in the long term to the well-being of the recipients (*Pérez-San-Gregorio et al.*, 2006), and depressive symptoms after liver transplantation are associated with an increased risk of long-term mortality (*Corruble et al.*, 2011). As a result, longitudinal studies and prolonged follow – up are required to disclose other possible factors that might undermine the psychological health of recipients (*Corruble et al.*, 2011).

### Aim of the Work

#### This Study Aims to Evaluate:-

- 1- Quality of life after LDLT in Egyptian recipients using short form 36 (SF-36) score.
- 2- Impact of post transplant medical and psychiatric complications on quality of life.

### Chapter (I)

### **End Stage Liver Disease**

Cirrhosis represents a late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and the formation of regenerative nodules. It is generally considered to be irreversible in its advanced stages at which point the only option may be liver transplantation. In earlier stages, specific treatments aimed at the underlying cause of liver disease can improve or even reverse cirrhosis (*Iwaisako et al.*, 2012).

Patients with cirrhosis are susceptible to a variety of complications and their life expectancy can be markedly reduced. Cirrhosis accounted for approximately 49,500 deaths and was the eighth leading cause of death in the United States in 2010. In addition, there were an estimated 19,500 deaths due to liver cancer, which often occurs in the setting of cirrhosis. Similarly, a study that used data from the National Death Index from the Centers for Disease Control and Prevention and the Rochester Epidemiology Project estimated that liver disease was responsible for 66,007 deaths in 2008, of which 18,175 were due to hepatobiliary cancer (*Asrani et al.*, 2013).

<u>Major Complications</u>: Major complications of cirrhosis include (table 1):